Self Nucleocapsid Protein Antigen Covid 19 Rapid Test Kit GICA Colloidal Gold 18*4*8cm

Covid-19 Rapid Antigen Detection Kit (GICA)

Theory of the Test

The SARS-CoV-2 Antigen Test Kit (GICA) is a colloidal gold enhanced double antibody sandwich immunoassay for the qualitative determination of nucleocapsid (N) protein of SARS-CoV-2 virus in human nasal (anterior) swab.

SARS-CoV-2 antibody is immobilized in the test region on nitrocellulose membrane. If the specimen contains SARS-CoV-2 antigen, during the assay specimen is allowed to react with the colored conjugate (SARS-CoV-2 antibody-colloidal gold conjugate); the mixture then migrates chromatographically on the membrane by the capillary action. An SARS-CoV-2 positive specimen produces a distinct color band in the test region, formed by the specific antibody antigen colored conjugate complex "(Au-SARS-CoV-2-Ab)-(SARS-CoV-2-Ag)- (SARS-CoV-2-Ab)". Absence of this colored band in the test region suggests a negative result. A colored band always appears in the control region serving as procedural control regardless of the specimen contains SARS-CoV-2 or not.

Product Specifications

Interpret Result

Positive Result: If you see two lines, Both the control line (C) and test line (T) appear. This means that SARS-CoV-2 antigen was detected. NOTE: Any faint line in the test line region (T) should be considered positive.

Negative Result: If you see only the Control (C) line is present,and no test(T) line present, this means that SARS-CoV-2 antigen was not detected.

Invalid Result: Find the result window. If Control line (C) fails to appear, the test did not work and is considered Invalid

Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan District, Shenzhen, P.R. China. is a diagnostics company focused on the development and manufacture of IVD tests at the Point-of-Care with highly innovative proprietary technology.

We focused on the emerging markets of in vitro pathological diagnosis and immunodiagnosis. We developed, manufactured and successfully launched the in vitro immunodiagnosis platform for cancer and the POCT for infectious, genetic and chronic diseases.

<span style="color: rgb(33, 33, 33); text-transform: none; text-indent: 0px; letter-spacing: normal;" initial;"="" initial;="" 0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;="" !important;="" inline="" none;="" 600;="" 14px;="" sans-serif;="" arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",="" hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,="" freesans,="" yahei",="" "microsoft="" helvetica,="" grande",="" "lucida="" ui",="" segoe="">At Kissh we work every day to shape the future of in-vitro diagnostic testing. And our people are our best asset, the reason for our track record and our strength while we are moving forward. We live by our fundamental values and incorporate them in everything that we do. Our best asset is ‘Step Forward Every Second’